Pharmaceutical Executive-05-01-2017

In its 11th annual feature, Pharm Exec breaks a bit from the norm, to instead profile five products that are shining the spotlight on five critical and highly debated aspects of healthcare and R&D at the moment.

With this year marking our 11th installment, we look back on Pharm Exec's first 10 Brands of the Year-why they were chosen and the challenges, changes, and successes since.

For pharma, diagnosing what ails or strengthens performance in this critical corporate discipline may help reshape business prognosis.

Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.

New DTC campaign for its vaccine Zostavax uses a more serious, personal messaging approach-as pharmas look to close the conversation gaps between patients and healthcare providers.

Payers and pharma companies seek outcomes data for evidence-based reimbursement deals.

Recent PR disasters in other industries raise an important reputational question that can apply to pharma as well: do you want to be someone that works the system or improves the system?

If pharma companies want to hold their own in the current climate, they must embrace rather than resist market change.

Grant-boosted Euripid pushes revitalized defense of external reference pricing system.

Home to some of the world’s most important international health institutions and some big pharma players as well, Switzerland lays claim as a healthcare and life sciences powerhouse. Navigating its pharmaceutical market terrain, however, does not come without its challenges.

Click the title above to open the Pharmaceutical Executive May 2017 issue in an interactive PDF format.